Drug Trial Radar · NCT03858036
Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders
Last checked: Nov 19, 2026Latest source record: Feb 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
550
Planned (sponsor's estimate)
Start
Mar 8, 2019
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Center for Sight, Sacramento, CAAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, single investigative site study to compare the safety and effectiveness of Epi-OFF CXL treatment (performed using Ricrolin+ and VEGA UV-A system) compared to Epi-ON CXL (performed using Ricrolin+ and VEGA UV-A system) in eyes with keratoconus and other corneal ectatic disorders.Subjects will be randomized to receive the CXL treatment with either the Epi-On or Epi-Off technique.
Conditions
- Keratoconus
- Ectasia
Interventions
Ricrolin+Drug
1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
VEGA UV-A systemDevice
The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in corneal curvatureTime frame: Baseline, 6 Months, and 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Sight
Sacramento, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.